{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:40:57Z","timestamp":1788212457657,"version":"build-2803163510"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Reduced-intensity regimens such as treosulfan-fludarabine (TF) are currently considered cornerstones for older or comorbid patients with acute myeloid leukemia and myelodysplastic syndrome (AML\/MDS) undergoing allogeneic hematopoietic stem cell transplant (alloSCT). However, data on its use in active disease cases are limited, and intensification strategies (such as thiotepa addition [TTF]) are not standardized in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>To evaluate the efficacy and tolerability of treosulfan-based conditioning in the real-world setting and to provide insights into the use of thiotepa intensification, we retrospectively analyzed 66 (AML, n\u2005=\u200558; MDS, n\u2005=\u20058) patients transplanted between January 2016 and December 2023 at the Hematology Division of Udine, receiving TF (n\u2005=\u200548) or TTF (n\u2005=\u200518).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      At alloSCT, the median age was 67 y; 37 patients (56%) had a hematopoietic cell transplantation-comorbidity index of &gt;2, and 13 (20%) had received previous alloSCT. Complete remission status was achieved by 52 (79%). A matched donor was used in 35 cases (53%). With a median follow-up of 16 mo, the cumulative incidences of 100-d grade \u22652 acute graft-versus-host disease and 3-y moderate-to-severe chronic graft-versus-host disease were 34% and 21%, respectively. After 3 y, cumulative incidences of nonrelapse mortality and disease relapse were 18% and 40%, with 46% progression-free survival and 52% overall survival. The TTF cohort included more cases with active disease status at alloSCT, both cytological (43% versus 12%,\n                      <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                      =\u20050.005) and minimal residual disease positive (90% versus 40%,\n                      <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                      =\u20050.005), compared with TF. Nevertheless, survival analysis confirmed no difference in nonrelapse mortality, progression-free survival, and overall survival among groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Our results confirmed the efficacy and tolerability of the TF regimen in older or comorbid AML and MDS patients in the real-world setting and suggest that double alkylation might counterbalance the adverse outcome risk posed by active disease at alloSCT. Furthermore, larger, prospective studies are needed to better elucidate the patients for whom the addition of thiotepa might be most beneficial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/txd.0000000000001896","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:01:12Z","timestamp":1768971672000},"page":"e1896","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Intensification of Treosulfan-Fludarabine Conditioning With Thiotepa Exhibited Effectiveness and Tolerability in Older or Comorbid Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With Active Myeloid Neoplasm: A Real-world Study"],"prefix":"10.1097","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3240-3186","authenticated-orcid":false,"given":"Luca","family":"Tosoni","sequence":"first","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"},{"name":"Department of Medicine (DMED), University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Facchin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Plos","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"},{"name":"Department of Medicine (DMED), University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Callegari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"},{"name":"Department of Medicine (DMED), University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fanin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"},{"name":"Department of Medicine (DMED), University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Martino","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Lisa","family":"Battista","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Geromin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"},{"name":"Department of Medicine (DMED), University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy"},{"name":"Department of Medicine (DMED), University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"R1-20260127","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/bmt.2011.242","article-title":"Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning.","volume":"47","author":"Casper","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R2-20260127","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","article-title":"Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.","volume":"96","author":"Ruutu","year":"2011","journal-title":"Haematologica"},{"key":"R3-20260127","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3.","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"key":"R4-20260127","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.26620","article-title":"Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial.","volume":"97","author":"Beelen","year":"2022","journal-title":"Am J Hematol"},{"key":"R5-20260127","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41409-024-02241-2","article-title":"Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients\u2014a clinical trial to registry data comparison.","volume":"59","author":"Beelen","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R6-20260127","doi-asserted-by":"crossref","first-page":"e952","DOI":"10.1097\/HS9.0000000000000952","article-title":"Thiotepa-busulfan-fludarabine compared to treosulfan-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with acute myeloid leukemia in remission: a study from the acute leukemia working party of the EBMT.","volume":"7","author":"Saraceni","year":"2023","journal-title":"HemaSphere"},{"key":"R7-20260127","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","article-title":"Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation.","volume":"25","author":"Dul\u00e9ry","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R8-20260127","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.25225","article-title":"Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.","volume":"93","author":"Saraceni","year":"2018","journal-title":"Am J Hematol"},{"key":"R9-20260127","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41409-023-02023-2","article-title":"Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.","volume":"58","author":"Cassanello","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R10-20260127","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41409-022-01777-5","article-title":"Thiotepa\u2013fludarabine\u2013treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.","volume":"57","author":"Finke","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R11-20260127","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"R12-20260127","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R13-20260127","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/leu.2010.312","article-title":"Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European Leukemianet Work Package 10.","volume":"25","author":"B\u00e9n\u00e9","year":"2011","journal-title":"Leukemia"},{"key":"R14-20260127","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT).","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R15-20260127","doi-asserted-by":"crossref","first-page":"96.e1","DOI":"10.1016\/j.jtct.2021.11.006","article-title":"GITMO registry study on allogeneic transplantation in patients aged \u226560 years from 2000 to 2017: improvements and criticisms.","volume":"28","author":"Malagola","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R16-20260127","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT.","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"R17-20260127","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41409-024-02275-6","article-title":"Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).","volume":"59","author":"Maffini","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R18-20260127","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.30646","article-title":"Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the acute leukemia working party of the european society for blood and marrow transplantation.","volume":"123","author":"Nagler","year":"2017","journal-title":"Cancer"},{"key":"R19-20260127","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41409-022-01600-1","article-title":"Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience.","volume":"57","author":"Piemontese","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R20-20260127","doi-asserted-by":"crossref","first-page":"e1451","DOI":"10.1097\/TXD.0000000000001451","article-title":"Busulfan or treosulfan conditioning platform for allogeneic stem cell transplantation in patients aged >60 y with acute myeloid leukemia\/myelodysplastic syndrome: a subanalysis of the GITMO alloeld study.","volume":"9","author":"Malagola","year":"2023","journal-title":"Transplant Direct"},{"key":"R21-20260127","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","article-title":"T cell regeneration after immunological injury.","volume":"21","author":"Velardi","year":"2021","journal-title":"Nat Rev Immunol"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:00:17Z","timestamp":1769515217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001896","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}